Almirall SA
MAD:ALM

Watchlist Manager
Almirall SA Logo
Almirall SA
MAD:ALM
Watchlist
Price: 10.2 EUR 2.62% Market Closed
Market Cap: 2.2B EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ALM stock under the Base Case scenario is 14.55 EUR. Compared to the current market price of 10.2 EUR, Almirall SA is Undervalued by 30%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALM Relative Value
Base Case
14.55 EUR
Undervaluation 30%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.2
P/S
P/S
Price to Sales
2.2
vs History
12
vs Industry
59
Median 3Y
1.5
Median 5Y
1.5
Industry
2.4
Forward
2
More Details
214.6
P/E
P/E
Price to Earnings
214.6
vs History
6
vs Industry
0
Median 3Y
-53.6
Median 5Y
10.6
Industry
20.3
Forward
33.3
More Details
13.5
P/OCF
P/OCF
Price to OCF
13.5
vs History
33
vs Industry
29
Median 3Y
12.9
Median 5Y
12.6
Industry
15.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
10
Median 3Y
-7.3
Median 5Y
-3.7
Industry
23.1
More Details
1.5
P/B
P/B
Price to Book Value
1.5
vs History
33
vs Industry
49
Median 3Y
1.3
Median 5Y
1.3
Industry
2
More Details
2.2
EV/S
EV/S
Enterprise Value to Sales
2.2
vs History
14
vs Industry
59
Median 3Y
1.5
Median 5Y
1.7
Industry
2.5
Forward
2
More Details
2.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.9
vs History
17
vs Industry
69
Median 3Y
2.1
Median 5Y
2.3
Industry
4.8
More Details
11.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
11.6
vs History
6
vs Industry
30
Median 3Y
10.1
Median 5Y
9.2
Industry
12.5
Forward
9.5
More Details
44.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
44.2
vs History
9
vs Industry
12
Median 3Y
32.5
Median 5Y
21
Industry
15.7
Forward
25.3
More Details
13.6
EV/OCF
EV/OCF
Enterprise Value to OCF
13.6
vs History
38
vs Industry
29
Median 3Y
13
Median 5Y
12.7
Industry
14.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
8
Median 3Y
-17.6
Median 5Y
17.9
Industry
17.6
More Details
1.2
EV/IC
EV/IC
Enterprise Value to IC
1.2
vs History
17
vs Industry
53
Median 3Y
1
Median 5Y
1
Industry
1.8
More Details

Multiples Across Competitors

ALM Competitors Multiples
Almirall SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
ES
Almirall SA
MAD:ALM
2.2B EUR 2.2 214.6 11.6 44.2
US
Eli Lilly and Co
NYSE:LLY
778.5B USD 15.9 70.1 37.6 41.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.9B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 7 20.2 13.3 15.1
CH
Roche Holding AG
SIX:ROG
216.3B CHF 3.6 26.1 9.8 11.5
CH
Novartis AG
SIX:NOVN
182.1B CHF 4.1 17.2 10.1 13.6
UK
AstraZeneca PLC
LSE:AZN
166.7B GBP 4 28.5 130.9 197.4
US
Merck & Co Inc
NYSE:MRK
209.4B USD 3.3 12 8.6 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
120.3B EUR 1.3 9.5 5.2 6.1
P/E Multiple
Earnings Growth PEG
ES
Almirall SA
MAD:ALM
Average P/E: 46.1
214.6
141%
1.5
US
Eli Lilly and Co
NYSE:LLY
70.1
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
18%
1.1
CH
Roche Holding AG
SIX:ROG
26.1
32%
0.8
CH
Novartis AG
SIX:NOVN
17.2
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.5
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.5
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ES
Almirall SA
MAD:ALM
Average EV/EBITDA: 395.2
11.6
19%
0.6
US
Eli Lilly and Co
NYSE:LLY
37.6
31%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
14%
1
CH
Roche Holding AG
SIX:ROG
9.8
6%
1.6
CH
Novartis AG
SIX:NOVN
10.1
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.9
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.6
9%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.2
8%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ES
Almirall SA
MAD:ALM
Average EV/EBIT: 1 701.2
44.2
56%
0.8
US
Eli Lilly and Co
NYSE:LLY
41.1
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
CH
Novartis AG
SIX:NOVN
13.6
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.4
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.3
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
6.1
14%
0.4

See Also

Summary
ALM intrinsic value, competitors valuation, and company profile.
DCF Valuation
ALM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ALM stock valuation using valuation multiples.
Wall Street Estimates
ALM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ALM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 252,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.